((This story was generated using AI and automation, please see
disclaimer https://bit.ly/rtrsnai))
Overview
* US medical device maker's Q3 revenue up 0.2% yr/yr, slightly beating analyst expectations
* Adjusted diluted EPS for Q3 rose to $2.63, beating consensus
* Company repurchased $350 mln in stock since July 1, 2026
Outlook
* Teleflex maintains 2026 pro forma adjusted constant currency revenue growth guidance at 3.5%-4.5%
* Company raises 2026 adjusted diluted EPS guidance to $7.50-$7.75 from continuing operations
* Teleflex lowers 2026 GAAP revenue growth guidance to 13.2%-14.2% due to foreign exchange changes
Result Drivers
* SEGMENT PERFORMANCE - Vascular and Surgical units delivered mid-single-digit growth, while Interventional returned to modest growth, per CEO Jason Weidman
* TARIFF REFUNDS - Q3 results benefited from $16.5 mln in IEEPA tariff refunds recognized in continuing operations
* MARGIN EXPANSION - Co cited margin expansion as contributing to robust EPS growth, even when excluding tariff refunds, per CEO Jason Weidman
Company press release: ID:nBwvY6jfa
Key Details
Metric Beat/Miss Actual Consensus
Estimate
Q3 Revenue Slight Beat* $567.78 mln $566.77 mln
(11
Analysts)
Q3 Adjusted Beat $2.63 $1.90 (12
EPS Analysts)
Q3 EPS $1.30
continuing
operations
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"
* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
* Wall Street's median 12-month price target for Teleflex Incorporated is $155.00, about 3.4% above its November 4 closing price of $149.87
* The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 15 three months ago
Reuters Recommended Reads
* Nov 4 - Insulet Q3 revenue beats estimates on strong Omnipod sales
* Nov 3 - AtriCure Q3 revenue beats expectations on strong sales of pain management and appendage devices
* Nov 4 - LivaNova Q3 revenue beats estimates on cardiopulmonary segment strength
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)